What I have: eGFR · HbA1c · tirzepatide.
I want to know what the trade-off actually is rather than which option is fashionable.
I would rather have a defensible reason than a marginal improvement.
What does each option buy me, and what does it cost me?
The short version: a small, well-chosen panel with a baseline beats a large one without.
A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Decide the action for each result before you order the test.
The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.
Keep the full report, not the number. You will need the units and the interval later.
Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
Research-use compounds are not approved for human use, and no panel makes that safer.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
edited 14 Sept 2025 by deamidation_watch — removed a claim I could not source
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.